ARTICLE | Company News
Hetero Drugs sales and marketing update
September 14, 2015 7:00 AM UTC
Hetero launched Maball rituximab in India to treat non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Maball is a biosimilar of MabThera/ Rituxan rituximab from Roche (SIX:ROG; OTC...